JP3893319B2 - Method for monitoring infant atopic dermatitis - Google Patents
Method for monitoring infant atopic dermatitis Download PDFInfo
- Publication number
- JP3893319B2 JP3893319B2 JP2002147498A JP2002147498A JP3893319B2 JP 3893319 B2 JP3893319 B2 JP 3893319B2 JP 2002147498 A JP2002147498 A JP 2002147498A JP 2002147498 A JP2002147498 A JP 2002147498A JP 3893319 B2 JP3893319 B2 JP 3893319B2
- Authority
- JP
- Japan
- Prior art keywords
- atopic dermatitis
- keratinocytes
- infant
- size
- index
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010012438 Dermatitis atopic Diseases 0.000 title claims description 57
- 201000008937 atopic dermatitis Diseases 0.000 title claims description 57
- 238000000034 method Methods 0.000 title claims description 35
- 238000012544 monitoring process Methods 0.000 title claims description 20
- 210000002510 keratinocyte Anatomy 0.000 claims description 48
- 229940079593 drug Drugs 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 20
- 210000000736 corneocyte Anatomy 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 12
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 206010003645 Atopy Diseases 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims 1
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 230000035876 healing Effects 0.000 description 5
- 239000002390 adhesive tape Substances 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960001235 gentian violet Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960001506 brilliant green Drugs 0.000 description 2
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Description
【０００１】
【発明の属する技術分野】
本発明は、乳幼児に於けるアトピー性皮膚炎の程度の鑑別法、その治癒経過のモニタリング方法、使用薬剤の適性度の鑑別法及びその為のキットに関する。
【０００２】
【従来の技術】
アトピー性皮膚炎と呼ばれている１群の皮膚炎は、近年においてその患者数を著しくのばし、年齢を問わず人口の数％〜数十％に上るとも言われている。その原因についてはアレルギーが起因しているとか、ストレスの要因が大きい等のように種々の説が提出されているが、実のところは明確になっていないのが現状である。言い換えれば、原因不明な掻痒を伴う皮膚炎を現象的にアトピー性皮膚炎と名付けているに過ぎず、その実態には多くの種類の皮膚炎が存在しているとも言われている。成人に於けるアトピー性皮膚炎では、主としてインドメタシン、イブプロフェン、ケトプロフェン、ケトチフェン等のノンステロイド抗炎症剤を投与したり、デキサメタゾン、プレドニゾロンなどの抗炎症ステロイドを投与したり、或いは尿素、グリセリンなどの保湿因子の高い皮膚外用剤を投与して、その予後を判別しつつ、薬剤の種類を変えて治療する手段が取られている。これは、成人においては掻痒の程度が言葉によって比較的的確に表現できるため、薬の効果のフィードバックが速やかに行えるからである。それに反して、乳幼児のアトピー性皮膚炎においては、言語的表現能力が無いが故に、ひっかき傷などの状況を見て薬効の判断を行わなければならず、症状に適した薬剤の選択がしにくい状況があった。又、乳幼児は所謂母体からの移行抗体に免疫を依存している時期であり、アトピー性皮膚炎のメカニズムとしてもアレルギーなどを原因とするものはそう多くはないように思われ、成人のアトピー性皮膚炎とは大きく異なることが推測される。この様な推測は多くの小児科医が経験的に持っている実感と一致している。言い換えれば、乳幼児のアトピー性皮膚炎においては、成人アトピー性皮膚炎の治療指針はあまり参考にはならず、しかも、その程度、或いは治療推移のモニタリングも鑑別しにくいことが適切な薬剤選択を阻害し、治療に於ける大きな問題となっている。
【０００３】
一方、成人アトピー性皮膚炎において、その程度や治癒過程のモニタリングが、角質細胞の大きさをもとに行えることは既に知られている。この様な角質細胞としては、疾患の部位の角質細胞を使用することが必要であり、これは、炎症によって生じるターンオーバーの昂進状況の代替値として角質細胞の大きさが捉えられているからである。又、基本的なアトピー性皮膚炎を起こしやすいか否かの体質的な鑑別は、患部ではなく、上腕内側部などの外部変化を受けにくい場所の角質細胞の大きさを指標に鑑別できることも知られている。しかしながら、かかる上腕内側部などの外部変化を受けにくい場所の角質細胞の大きさを指標に、アトピー性皮膚炎の治癒過程をモニタリングすることは相関性が低く困難であった。この為、相関性の高い頬部などの角質細胞の大きさを指標として用いていた。
【０００４】
従って、乳幼児に於けるアトピー性皮膚炎において、採取した前記乳幼児の角質細胞の大きさを指標とし、アトピー性皮膚炎の程度、治癒過程のモニタリング、使用薬剤の適切性などを判断することはおこなわれていなかった。
【０００５】
【発明が解決しようとする課題】
本発明は、この様な状況下為されたものであり、乳幼児のアトピー性皮膚炎において、その程度、治療推移のモニタリング、適切な薬剤を鑑別する手段を提供することを課題とする。
【０００６】
【課題の解決手段】
この様な状況に鑑みて、本発明者らは、乳幼児のアトピー性皮膚炎において、その程度、治療推移のモニタリング、適切な薬剤を鑑別する手段を求めて、鋭意研究努力を重ねた結果、乳幼児の角質細胞を採取し、この角質細胞の大きさを計測し、それを指標とすることにより、その様な技術が可能であることを見出し、発明を完成させるに至った。即ち、本発明は、以下に示す技術に関するものである。尚、本発明に言う、乳幼児とは、授乳状態にある乳児から幼児の総称を意味し、おおむね５歳までの幼児をさす。
（１）乳幼児に於けるアトピー性皮膚炎症状において、採取した前記乳幼児の角質細胞の大きさを指標とすることを特徴とする、アトピー性皮膚炎の程度の鑑別法。
（２）角質細胞の大きさが角質細胞面積であることを特徴とする、（１）に記載のアトピー性皮膚炎の程度の鑑別法。
（３）角質細胞の採取部位が上腕内側部であることを特徴とする、（１）又は（２）に記載のアトピー性皮膚炎の程度の鑑別法。
（４）角質細胞が大きいほどアトピー性皮膚炎は軽度である、及び／又は、角質細胞が小さいほどアトピー性皮膚炎は重篤であると鑑別することを特徴とする、（１）〜（３）何れか１項に記載のアトピー性皮膚炎の程度の鑑別法。
（５）乳幼児に於けるアトピー性皮膚炎の治療において、採取した前記乳幼児の角質細胞の大きさを指標とすることを特徴とする、治療効果のモニタリング方法。
（６）角質細胞の大きさが角質細部面積であることを特徴とする、（５）に記載のモニタリング方法。
（７）角質細胞の採取部位が上腕内側部であることを特徴とする、（５）又は（６）に記載のモニタリング方法。
（８）角質細胞が大きくなるほどアトピー性皮膚炎は良好に治癒していると判断する、及び／又は、角質細胞が小さくなるほどアトピー性皮膚炎は重篤に推移していると判断することを特徴とする、（５）〜（７）何れか１項に記載のモニタリング方法。
（９）乳幼児に於けるアトピー性皮膚炎の薬剤治療において、採取した前記乳幼児の角質細胞の大きさを指標とすることを特徴とする、使用薬剤の適性度の鑑別法。
（１０）角質細胞の大きさが角質細胞面積であることを特徴とする、（９）に記載の使用薬剤の適性度の鑑別法。
（１１）角質細胞の採取部位が上腕内側部であることを特徴とする、（９）又は（１０）に記載の使用薬剤の適性度の鑑別法。
（１２）角質細胞が大きいほどアトピー性皮膚炎は軽度である、及び／又は、角質細胞が小さいほどアトピー性皮膚炎は重篤であると鑑別することを特徴とする、（９）〜（１１）何れか１項に記載の使用薬剤の適性度の鑑別法。
（１３）次に示す構成部品を必須構成要素として有する、乳幼児のアトピー性皮膚炎の鑑別又はモニタリングのためのキット。
（構成部品１）角質細胞採取用の粘着テープ
（構成部品２）角質細胞の染色剤
（構成部品３）角質細胞の大きさの計測装置
【０００７】
【発明の実施の形態】
本発明の乳幼児に於けるアトピー性皮膚炎の程度の鑑別法は、採取した前記乳幼児の角質細胞の大きさを指標とすることを特徴とする。大きさとしては、面積、体積、角質細胞の周辺の長さの平均値の何れもが使用できるが、計測の簡便性から面積をも用いるのが特に好ましい。この様な角質細胞の大きさの測定方法は既に多くの技術が知られておりそれらを利用或いは応用することができる。具体的な方法については、特開２００２−１７６８８号、特開２００１−１０８６７４号、特開２００１−１３１３８号、特開２０００−１１６６２３号、特開平１１−３０４７９８号、特開平１１−２９９７９２号、特開平７−２０９２９２号等の記載を参考にすることができる。この様な測定を行うためには、顔や上腕内側部などの体部の何れかの部位から角質細胞を採取し、角質細胞を作成することが好ましい。即ち、顔の頬、額、上腕内側部、大腿部などの部位より粘着テープや粘着剤を塗工したディスクなどの粘着支持体を用いて、これらを押しつけ、しかる後に剥離し、ストリッピングにより角質細胞を採取したものが好適に例示できる。粘着支持体としては、均一性の点でディスクに粘着剤を塗工した形態が更に好ましく例示できる。又、押しつける作業も２、３回行い、ムラをなくすことが好ましい。この場合、本発明においては、乳幼児を対象にするため、この際、更にもう一度粘着支持体を用いて角質細胞を転写し、角質細胞の表面側の面を上面にし、この面を観察することもできる。この様な転写を行うことは、角質細胞を均一な一層にすることができるので、角質細胞の形状の理解にとっては好ましい。かかる角質細胞の採取部位としては、本発明においては上腕内側部が特に好ましい。これはこの部位に於ける角質細胞の方が頬部などの濾紙粒に於ける角質細胞よりも、よりアトピー性皮膚炎の状況に相関しているためである。このことからも乳幼児のアトピー性皮膚炎の素因が成人のそれとは異なる可能性があることを示唆している。かくして得られた角質細胞は、形状が明らかになるように染色することが好ましい。染色法としては、細胞質が染色されるものであれば特段の限定はないが、ブリリアントグリーンとゲンチアナバイオレットによる二重染色が好ましい、乳幼児の角質細胞は染色されにくいため、かかる染色液は、成人に比べて濃いめに、浸漬時間は長くすることが好ましい。染色剤の濃度としては、ブリリアントグリーンが０．４〜２重量％が好ましく、０．４〜１重量％が更に好ましい。ゲンチアナバイオレットは３重量％までがこのましく、０．９〜２重量％が更に好ましい。浸漬時間は、温度２０〜４０℃で、１０〜４０分が好ましく、１５〜３０分が特に好ましい。かくして得られた染色された標本は、顕微鏡やビデオマイクロスコープなどを通して画像として取り込んで「フォトショップ」（登録商標）などの市販の画像処理ソフトを用いて、画像処理し面積を計測することが好ましい。この様な測定は以下に示す構成要素を最低限含むキットによって作成された標本を用いることによってなし得る。即ち、（構成部品１）角質細胞採取用の粘着テープ（構成部品２）角質細胞の染色剤及び（構成部品３）角質細胞の大きさの計測装置の３つであり、これ以外に所望により、転写用の粘着体や染色槽、バルサムなどの封入剤などを加えることもできる。これが本発明のキットである。
【０００８】
本発明の乳幼児のアトピー性皮膚炎の程度の鑑別法は前記角質細胞の大きさを指標とすることを特徴とする。この時、大きさとアトピー性皮膚炎の程度との関係は、角質細胞が大きいほどアトピー性皮膚炎は軽度であり、角質細胞が小さいほどアトピー性皮膚炎は重篤であることが目安となる。かかる角質細胞大きさの標準値（正常値）は部位により異なるが、平均値を取ってみると、頬部では７００μｍ２前後であり、上腕内側部では８００μｍ２前後である。
【０００９】
前記の原理を利用すると、個人個人の角質細胞の大きさをトレースをすることにより、アトピー性皮膚炎の重篤度或いは軽快度がモニタリングすることができる。乳幼児に於いては病態についての意思伝達ができないため、治療、投薬によって掻痒などの感覚的変化の有無が把握しにくく、処置や投与した薬剤の有効性を確かめることはこれまでは不可能であったが、本発明のモニタリング方法によって、この様な有効性の把握が可能となっている。
【００１０】
前記のモニタリングが投薬された薬剤に関するものが、本発明の使用薬剤の適性の鑑別法となる。
【００１１】
【実施例】
以下に実施例を挙げて、本発明について更に詳細に説明を加えるが、本発明がこれら実施例にのみ限定されないことは言うまでもない。
【００１２】
＜実施例１＞
健常な０歳児（９ヶ月以下）５５名と医師によってアトピー性皮膚炎と判断された０歳児（９ヶ月以下）１２名について、頬部及び上腕内側部より角質細胞を採取し、０．５％ブリリアントグリーン水溶液に４０℃１５分、１％ゲンチアナバイオレット水溶液に４０℃１５分浸漬し、顕微鏡を介してデジタル画像を取り込み、「フォトショップ」で輝度調整を行い、角質細胞を明確にし、これより面積を測定した。結果を図１に示す。これより、上腕内側部の角質細部面積に於いて、アトピー患者が健常人に比べて有意に小さくなっていることがわかる。尚、角質細胞の標本は粘着剤を塗工したディスク（直径２ｃｍ）を部位に２回押しつけ、剥離した後、粘着テープに転写し採取したものを染色して用いた。
【００１３】
＜実施例２＞
生後６ヶ月のアトピー性皮膚炎の患者に、「ヒルドイド」による治療を試みた。同時に、頬部、上腕内側部から治療前、治療開始１１日、８１日に実施例１と同様に角質細胞を採取し、標本を作製し、角質細胞の面積を測定した。同時に、症状についてスコア０（全くなし）からスコア４（非常に著しい、重篤）までのランクで、紅斑、丘疹、乾燥・落屑、掻破痕、その他の症状を医師が判別した。結果を図２に示す。これより、本発明のモニタリング方法によって、アトピー性皮膚炎の治癒経過が適切にモニタリングできることがわかる。
【００１４】
＜実施例３＞
生後５ヶ月のアトピー性皮膚炎患者を「ヒルドイド」の投与で１４日間治療したが、上腕内側部の角質細胞面積は、治療前７２４μｍ２であり、治療開始１４日で７１９μｍ２であり、効果が出ていないと判断し、薬剤をプレドニゾロン軟膏に変えたところ、投与１４日で７６１μｍ２となり有効性が確かめられた。これより本発明の薬剤の適性の鑑別法により適切な薬剤が選択できることがわかる。
【００１５】
【発明の効果】
乳幼児のアトピー性皮膚炎において、その程度、治療推移のモニタリング、適切な薬剤を鑑別する手段を提供することができる。
【図面の簡単な説明】
【図１】 実施例１の結果を示す図である。
【図２】 実施例２の結果を示す図である。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a method for discriminating the degree of atopic dermatitis in infants, a method for monitoring the progress of healing, a method for discriminating the suitability of drugs used, and a kit therefor.
[0002]
[Prior art]
In recent years, a group of dermatitis called atopic dermatitis has significantly increased the number of patients, and is said to be several percent to several tens of percent of the population regardless of age. Various theories have been submitted regarding the cause, such as allergies and the cause of stress, but the reality is that it is not clear. In other words, dermatitis with itching of unknown cause is merely named as atopic dermatitis in phenomenon, and it is said that there are many types of dermatitis in reality. For atopic dermatitis in adults, nonsteroidal anti-inflammatory drugs such as indomethacin, ibuprofen, ketoprofen, ketotifen, etc., antiinflammatory steroids such as dexamethasone, prednisolone, etc., or moisturizing such as urea, glycerin, etc. A means for treating by changing the type of drug while administering a topical skin preparation with a high factor and determining its prognosis has been taken. This is because, in adults, the degree of pruritus can be expressed relatively accurately with words, so that the effect of the drug can be quickly fed back. On the other hand, in atopic dermatitis of infants, because there is no language expression ability, it is necessary to judge the medicinal effect by looking at the situation such as scratches, and it is difficult to select a drug suitable for the symptom. There was a situation. Infants are also dependent on so-called maternal antibodies for immunity, and it seems that there are not many atopic dermatitis mechanisms that cause allergies. It is speculated that it is very different from dermatitis. Such assumptions are consistent with the experience that many pediatricians have empirically. In other words, in the treatment of atopic dermatitis in infants, the treatment guidelines for adult atopic dermatitis are not very helpful, and the level of treatment or the monitoring of treatment progress is difficult to distinguish. However, it is a big problem in treatment.
[0003]
On the other hand, in adult atopic dermatitis, it is already known that the degree and the healing process can be monitored based on the size of the keratinocytes. As such keratinocytes, it is necessary to use keratinocytes at the site of the disease, because the size of the keratinocytes is regarded as an alternative value of the turnover progress caused by inflammation. is there. In addition, it is also known that basic constitutional discrimination of whether or not it is likely to cause atopic dermatitis can be differentiated by using the size of keratinocytes in the place where it is difficult to undergo external changes such as the inner part of the upper arm, not the affected part, as an index. It has been. However, according to the index the magnitude of external changes less susceptible locations keratinocytes, such as the upper inner arm portion, it is correlated to monitor the healing process of atopic dermatitis is difficult lower. For this reason, the size of corneocytes such as cheeks with high correlation was used as an index.
[0004]
Therefore, in the case of atopic dermatitis in infants, it is not possible to judge the degree of atopic dermatitis, monitoring of the healing process, the appropriateness of the drug used, etc., using the size of the horny cells collected as an index. It wasn't.
[0005]
[Problems to be solved by the invention]
The present invention has been made under such circumstances, and it is an object of the present invention to provide means for monitoring the level of treatment, the transition of treatment, and discriminating appropriate drugs in atopic dermatitis in infants.
[0006]
[Means for solving problems]
In view of such a situation, the present inventors, as a result of intensive research efforts, seeking a means for identifying the degree, monitoring of the course of treatment, and identifying appropriate drugs in infants with atopic dermatitis, The keratinocytes were collected, the size of the keratinocytes was measured, and by using it as an index, it was found that such a technique was possible, and the present invention was completed. That is, this invention relates to the technique shown below. The term “infant” as used in the present invention means a general term for an infant in a nursing state to an infant, and generally refers to an infant up to five years old.
(1) A method for differentiating the degree of atopic dermatitis, characterized in that the size of the corneocytes of the collected infant is used as an index in the symptoms of atopic skin inflammation in infants.
(2) The method for distinguishing the degree of atopic dermatitis according to (1), wherein the size of the keratinocytes is the horny cell area.
(3) The method for distinguishing the degree of atopic dermatitis according to (1) or (2), wherein the corneocyte collection site is the inner part of the upper arm.
(4) Atopic dermatitis is milder as the keratinocytes are larger, and / or atopic dermatitis is more severe as the keratinocytes are smaller, (1) to (3 ) A method for differentiating the degree of atopic dermatitis according to any one of the above.
(5) A therapeutic effect monitoring method, characterized in that, in the treatment of atopic dermatitis in an infant, the size of the corneocytes of the collected infant is used as an index.
(6) The monitoring method according to (5), wherein the size of the keratinocytes is a horny detailed area.
(7) The monitoring method according to (5) or (6), wherein the corneocyte collection site is the inner part of the upper arm.
(8) It is judged that atopic dermatitis is healed better as keratinocytes become larger, and / or atopic dermatitis is judged to be more serious as keratinocytes become smaller. The monitoring method according to any one of (5) to (7).
(9) A method for discriminating the suitability of a drug to be used, characterized in that, in drug treatment of atopic dermatitis in an infant, the size of the corneocytes of the collected infant is used as an index.
(10) The method for distinguishing suitability of a drug used according to (9), characterized in that the size of the corneocytes is the corneocyte area.
(11) The method for distinguishing the suitability of a drug used according to (9) or (10), wherein the corneocyte collection site is the inner part of the upper arm.
(12) Atopic dermatitis is milder as keratinocytes are larger and / or atopic dermatitis is more severe as keratinocytes are smaller, (9) to (11 ) A method for discriminating the suitability of the drug used according to any one of the items.
(13) A kit for distinguishing or monitoring atopic dermatitis in infants, having the following components as essential components.
(Component 1) Adhesive tape for collecting keratinocytes (Component 2) Staining agent for keratinocytes (Component 3) Measuring device for size of keratinocytes
DETAILED DESCRIPTION OF THE INVENTION
The method for distinguishing the degree of atopic dermatitis in an infant of the present invention is characterized in that the size of the corneocytes of the collected infant is used as an index. As the size, any of area, volume, and average length around the corneocytes can be used, but it is particularly preferable to use the area from the viewpoint of simplicity of measurement. Many techniques for measuring the size of keratinocytes are already known, and they can be used or applied. Specific methods are described in JP-A-2002-17688, JP-A-2001-108674, JP-A-2001-13138, JP-A-2000-116623, JP-A-11-304798, JP-A-11-299792, The description of Kaihei 7-209292 and the like can be referred to. In order to perform such a measurement, it is preferable to collect keratinocytes from any part of the body part such as the face or the inner side of the upper arm to create keratinocytes. That is, using an adhesive support such as an adhesive tape or a disc coated with adhesive from the cheek, forehead, inner side of the upper arm, thigh, etc., pressing them, and then peeling them off by stripping What collected the corneocytes can be illustrated suitably. As the adhesive support, a form in which an adhesive is applied to the disk in terms of uniformity can be further exemplified. Further, it is preferable to perform the pressing operation a few times to eliminate unevenness. In this case, in the present invention, in order to target infants, at this time, the keratinocytes are further transferred once again using the adhesive support, the surface of the keratinocytes on the upper surface, and this surface may be observed. it can. Performing such transcription is preferable for understanding the shape of the keratinocytes because the keratinocytes can be made uniform in one layer. As the keratinocyte collection site, the inner side of the upper arm is particularly preferable in the present invention. This is because the corneocytes at this site correlate more with the situation of atopic dermatitis than the corneocytes in filter paper grains such as the cheeks. This also suggests that the predisposition of infant atopic dermatitis may be different from that of adults. The corneocytes thus obtained are preferably stained so that the shape becomes clear. There are no particular limitations on the staining method as long as the cytoplasm is stained, but double staining with brilliant green and gentian violet is preferred. It is preferable that the dipping time is longer than that of the darker one. The concentration of the staining agent is preferably 0.4 to 2% by weight, more preferably 0.4 to 1% by weight for brilliant green. Gentian violet is preferably up to 3% by weight, more preferably 0.9-2% by weight. The immersion time is 20 to 40 ° C., preferably 10 to 40 minutes, and particularly preferably 15 to 30 minutes. The stained specimen thus obtained is preferably captured as an image through a microscope, a video microscope, etc., and image-processed using a commercially available image processing software such as “Photoshop” (registered trademark) to measure the area. . Such a measurement can be made by using a sample prepared by a kit containing at least the following components. That is, (Component 1) Adhesive tape for collecting keratinocytes (Component 2) Staining agent for keratinocytes and (Component 3) Measuring device for the size of keratinocytes. It is also possible to add a transfer adhesive, a dyeing tank, an encapsulant such as balsam, and the like. This is the kit of the present invention.
[0008]
The method for distinguishing the degree of atopic dermatitis of an infant of the present invention is characterized in that the size of the keratinocytes is used as an index. At this time, the relationship between the size and the degree of atopic dermatitis is that the larger the keratinocytes, the milder the atopic dermatitis, and the smaller the keratinocytes, the more severe the atopic dermatitis. The standard value (normal value) of the horny cell size varies depending on the site, but taking an average value, it is around 700 μm 2 at the cheek and around 800 μm 2 at the inner side of the upper arm.
[0009]
By utilizing the above principle, the severity or remission of atopic dermatitis can be monitored by tracing the size of individual keratinocytes. Infants cannot communicate their pathological conditions, so it is difficult to determine the presence or absence of sensory changes such as pruritus by treatment and medication, and it has been impossible to confirm the effectiveness of treatments and administered drugs. However, such effectiveness can be grasped by the monitoring method of the present invention.
[0010]
A method for distinguishing the suitability of the drug used according to the present invention relates to the drug administered by the above monitoring.
[0011]
【Example】
Hereinafter, the present invention will be described in more detail with reference to examples, but it is needless to say that the present invention is not limited to these examples.
[0012]
<Example 1>
For 55 healthy 0-year-old children (9 months or less) and 12 0-year-old children (9 months or less) determined to be atopic dermatitis by a doctor, keratinocytes were collected from the cheek and inner arm, 0.5% Immerse in a Brilliant Green aqueous solution at 40 ° C for 15 minutes in a 1% gentian violet aqueous solution at 40 ° C for 15 minutes, capture a digital image through a microscope, adjust the brightness with "Photoshop", clarify the horny cells, and from this Was measured. The results are shown in FIG. From this, it can be seen that the atopic patient is significantly smaller than the healthy person in the horny detail area of the inner side of the upper arm. The sample of keratinocytes was used by dyeing a sample (2 cm in diameter) coated with an adhesive, pressing it twice on the site, peeling it, transferring it to an adhesive tape, and collecting it.
[0013]
<Example 2>
A 6-month-old atopic dermatitis patient was treated with "Hirudoid". At the same time, keratinocytes were collected from the cheeks and inner side of the upper arm before treatment, and on the 11th and 81st days of treatment in the same manner as in Example 1 to prepare specimens and measure the area of the keratinocytes. At the same time, doctors identified erythema, papules, dryness / desquamation, scratch marks, and other symptoms on a symptom rank from score 0 (none at all) to score 4 (very significant, severe). The results are shown in FIG. From this, it can be seen that the healing process of atopic dermatitis can be appropriately monitored by the monitoring method of the present invention.
[0014]
<Example 3>
Although atopic dermatitis patients five month old treated 14 days at a dose of "Hirudoid" keratinocyte area of the upper inner arm portion is a pre-treatment 724Myuemu 2 is 719Myuemu 2 at the start of treatment 14 days, the effect When it was determined that the drug was not discharged and the drug was changed to prednisolone ointment, the effectiveness was confirmed to be 761 μm 2 on the 14th day of administration. From this, it can be seen that an appropriate drug can be selected by the method for distinguishing the suitability of the drug of the present invention.
[0015]
【The invention's effect】
In atopic dermatitis in infants, it is possible to provide a means for monitoring the degree, monitoring of the course of treatment, and distinguishing appropriate drugs.
[Brief description of the drawings]
FIG. 1 is a diagram showing the results of Example 1. FIG.
FIG. 2 is a graph showing the results of Example 2.
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002147498A JP3893319B2 (en) | 2002-05-22 | 2002-05-22 | Method for monitoring infant atopic dermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002147498A JP3893319B2 (en) | 2002-05-22 | 2002-05-22 | Method for monitoring infant atopic dermatitis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003344390A JP2003344390A (en) | 2003-12-03 |
| JP2003344390A5 JP2003344390A5 (en) | 2005-07-21 |
| JP3893319B2 true JP3893319B2 (en) | 2007-03-14 |
Family
ID=29766544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002147498A Expired - Fee Related JP3893319B2 (en) | 2002-05-22 | 2002-05-22 | Method for monitoring infant atopic dermatitis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3893319B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11911012B2 (en) | 2017-03-03 | 2024-02-27 | Children's Hospital Medical Center | Non-invasive methods for skin sample collection and analysis |
-
2002
- 2002-05-22 JP JP2002147498A patent/JP3893319B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003344390A (en) | 2003-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Machtei et al. | Longitudinal study of predictive factors for periodontal disease and tooth loss | |
| Cordeira et al. | Learning and memory are impaired in the object recognition task during metestrus/diestrus and after sleep deprivation | |
| Hwang et al. | Association of frailty and cardiometabolic risk among community-dwelling middle-aged and older people: results from the I-Lan longitudinal aging study | |
| Marinoski et al. | Oral mucosa and salivary findings in non-diabetic patients with chronic kidney disease | |
| Amarbayasgalan et al. | Content of vascular endothelial growth factor in stratum corneum well correlates to local severity of acute inflammation in patients with atopic dermatitis | |
| Hachmo et al. | The effect of hyperbaric oxygen therapy on the pathophysiology of skin aging: a prospective clinical trial | |
| Bunyaratavej et al. | Skin scrapings versus standardized skin surface biopsy to detect Demodex mites in patients with facial erythema of uncertain cause–a comparative study | |
| JP2000513719A (en) | Diagnosis test of schizophrenia using niacin | |
| Tercedor et al. | Multivariate analysis of cutaneous markers of aging in chronic hemodialyzed patients | |
| BOWERS et al. | Naproxen in rheumatoid arthritis: a controlled trial | |
| JP3893319B2 (en) | Method for monitoring infant atopic dermatitis | |
| US20190145967A1 (en) | Index of local severity of atopic dermatitis in skin and therapeutic effect thereon | |
| Jeong et al. | Oral sarpogrelate can improve endothelial dysfunction as effectively as oral cilostazol, with fewer headaches, in active young male smokers | |
| WO2019063026A1 (en) | Method and test kit for supplementary screening of common mental disorders | |
| Tamara et al. | Association between magnesium levels and the severity of acne vulgaris | |
| Monson et al. | Oral Health Issues in Psoriasis: an overview of the literature | |
| CN115844796B (en) | Water-in-oil composition with acne removing, skin refreshing and slow release effects and application thereof | |
| RU2812602C2 (en) | Method of predicting type of course of lichen planus of oral mucosa | |
| Rashed et al. | Evaluation of the prevalence and risk of metabolic syndrome in vitiligo patients | |
| JP6397733B2 (en) | Acne Skin Evaluation Method | |
| RU2712079C1 (en) | Liposomal drug for treating local radiation damages of skin | |
| Абдугаппаров et al. | The results of clinical and laboratory studies in patients with disseminated pulmonary tuberculosis | |
| Ritschel | Identification of populations at risk in drug testing and therapy: application to elderly patients | |
| Eker et al. | Investigation of genotoxicity caused by oral isotretinoin use in acne treatment | |
| RU2354971C1 (en) | Method of monitoring effectiveness of treating chronic mycobacteriosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041126 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041126 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20041126 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20041126 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20060410 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060418 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060619 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060808 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060905 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20061128 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20061211 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |